UA111403C2 - ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ ДЛЯ ЛІКУВАННЯ ПУХЛИН, ЕКСПРЕСУЮЧИХ EGFR І N-ГЛІКОЛІЛГАНГЛІОЗИД GM3 (NeuGсGM3) - Google Patents

ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ ДЛЯ ЛІКУВАННЯ ПУХЛИН, ЕКСПРЕСУЮЧИХ EGFR І N-ГЛІКОЛІЛГАНГЛІОЗИД GM3 (NeuGсGM3)

Info

Publication number
UA111403C2
UA111403C2 UAA201408435A UAA201408435A UA111403C2 UA 111403 C2 UA111403 C2 UA 111403C2 UA A201408435 A UAA201408435 A UA A201408435A UA A201408435 A UAA201408435 A UA A201408435A UA 111403 C2 UA111403 C2 UA 111403C2
Authority
UA
Ukraine
Prior art keywords
treatment
glycolyl
pharmaceutical composition
malignant tumours
express egfr
Prior art date
Application number
UAA201408435A
Other languages
English (en)
Inventor
Паломо Адіс Гонсалес
Перес Адріана Карр
Монсон Калєт Лєон
Сантана Рансес Бланко
Альварес Марія дель Кармен Барросо
Абраам Ампаро Емілія Масіас
Касіміро Хосе Енріке Монтеро
Original Assignee
Сентро Де Інмунологіа Молекулар
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47435671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA111403(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сентро Де Інмунологіа Молекулар filed Critical Сентро Де Інмунологіа Молекулар
Publication of UA111403C2 publication Critical patent/UA111403C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Даний винахід стосується композиції для лікування злоякісного новоутворення, яка містить моноклональне антитіло проти рецептора епідермального фактора росту (EGFR) і вакцину проти N-гліколілгангліозиду GM3 (NeuGcGM3).
UAA201408435A 2011-12-27 2012-04-12 ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ ДЛЯ ЛІКУВАННЯ ПУХЛИН, ЕКСПРЕСУЮЧИХ EGFR І N-ГЛІКОЛІЛГАНГЛІОЗИД GM3 (NeuGсGM3) UA111403C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20110245A CU24070B1 (es) 2011-12-27 2011-12-27 Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
PCT/CU2012/000007 WO2013097834A1 (es) 2011-12-27 2012-12-04 COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE TUMORES QUE EXPRESAN REGF Y GANGLIÓSIDO N-GLICOLIL GM3 (NeuGcGM3)

Publications (1)

Publication Number Publication Date
UA111403C2 true UA111403C2 (uk) 2016-04-25

Family

ID=47435671

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201408435A UA111403C2 (uk) 2011-12-27 2012-04-12 ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ ДЛЯ ЛІКУВАННЯ ПУХЛИН, ЕКСПРЕСУЮЧИХ EGFR І N-ГЛІКОЛІЛГАНГЛІОЗИД GM3 (NeuGсGM3)

Country Status (26)

Country Link
US (1) US9790279B2 (uk)
EP (1) EP2805747B1 (uk)
JP (1) JP6027137B2 (uk)
KR (1) KR101703637B1 (uk)
CN (1) CN103998098B (uk)
AR (1) AR089490A1 (uk)
AU (1) AU2012361321C1 (uk)
BR (1) BR112014015693B1 (uk)
CA (1) CA2855182C (uk)
CL (1) CL2014001236A1 (uk)
CO (1) CO6990729A2 (uk)
CU (1) CU24070B1 (uk)
EA (1) EA030346B1 (uk)
ES (1) ES2694324T3 (uk)
IL (1) IL233323B (uk)
MX (1) MX359476B (uk)
MY (1) MY185138A (uk)
PE (1) PE20142328A1 (uk)
PH (1) PH12014501202A1 (uk)
SG (1) SG11201403014XA (uk)
TN (1) TN2014000203A1 (uk)
TR (1) TR201816232T4 (uk)
TW (1) TWI523663B (uk)
UA (1) UA111403C2 (uk)
WO (1) WO2013097834A1 (uk)
ZA (1) ZA201405424B (uk)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2144440T3 (es) * 1992-08-18 2000-06-16 Centro Inmunologia Molecular Anticuerpos monoclonales que reconocen el receptor del factor de crecimiento epidermico, celulas y metodos para su produccion y compuestos que los contienen.
CN1103404A (zh) * 1993-03-01 1995-06-07 分子免疫中心 识别表皮生长因子受体的新的单克隆抗体，生产这种抗体的细胞和方法以含有这种抗体的组合物
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
CU22731A1 (es) 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores

Also Published As

Publication number Publication date
BR112014015693A8 (pt) 2017-07-04
MX2014007919A (es) 2014-07-30
CN103998098B (zh) 2017-08-04
EP2805747B1 (en) 2018-10-17
TW201336509A (zh) 2013-09-16
IL233323B (en) 2018-11-29
KR20140100538A (ko) 2014-08-14
AU2012361321A8 (en) 2014-08-07
CA2855182C (en) 2018-06-12
JP2015506354A (ja) 2015-03-02
CO6990729A2 (es) 2014-07-10
PE20142328A1 (es) 2015-01-29
NZ627012A (en) 2016-01-29
BR112014015693B1 (pt) 2023-03-21
MY185138A (en) 2021-04-30
ES2694324T3 (es) 2018-12-19
CU24070B1 (es) 2015-01-29
KR101703637B1 (ko) 2017-02-07
WO2013097834A1 (es) 2013-07-04
CN103998098A (zh) 2014-08-20
JP6027137B2 (ja) 2016-11-16
AR089490A1 (es) 2014-08-27
EA030346B1 (ru) 2018-07-31
CU20110245A7 (es) 2013-08-29
MX359476B (es) 2018-09-27
AU2012361321A1 (en) 2014-07-24
AU2012361321B2 (en) 2015-11-19
US20140363494A1 (en) 2014-12-11
IL233323A0 (en) 2014-08-31
EA201491284A1 (ru) 2014-09-30
PH12014501202A1 (en) 2014-09-08
SG11201403014XA (en) 2014-09-26
AU2012361321C1 (en) 2016-03-10
EP2805747A1 (en) 2014-11-26
TWI523663B (zh) 2016-03-01
TN2014000203A1 (en) 2015-09-30
BR112014015693A2 (pt) 2017-06-13
US9790279B2 (en) 2017-10-17
CL2014001236A1 (es) 2014-08-08
TR201816232T4 (tr) 2018-11-21
CA2855182A1 (en) 2013-07-04
ZA201405424B (en) 2016-02-24

Similar Documents

Publication Publication Date Title
TN2015000396A1 (en) Antibody drug conjugates
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
IN2014KN00848A (uk)
NI201500024A (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
MX2014015830A (es) Anticuerpos lsr y usos de los mismos para el tratamiento de cancer.
CL2015001356A1 (es) Anticuerpos bioespecificos egfr/c-met
MX370199B (es) Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
MX340090B (es) Analogos de spliceostatina.
MA34091B1 (fr) Anticorps anti-cd40
EA201200999A1 (ru) Способы лечения рака молочной железы
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
UY34154A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel.
AR098221A1 (es) Conjugados de anticuerpo anti-efna4-fármaco
AR085105A1 (es) Dosificacion para tratamiento con anticuerpos anti-dominio 7 de tipo de factor de crecimiento epidermico (anti-egfl7)
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
UA111403C2 (uk) ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ ДЛЯ ЛІКУВАННЯ ПУХЛИН, ЕКСПРЕСУЮЧИХ EGFR І N-ГЛІКОЛІЛГАНГЛІОЗИД GM3 (NeuGсGM3)
HUE058745T2 (hu) Hatóanyagként epidermális növekedési faktor receptorhoz specifikusan kötõdõ antitestet tartalmazó gyógyászati készítmény rák áttételének gátlására
TH1401003675A (th) องค์ประกอบทางเภสัชกรรมสำหรับการรักษาเนื้องอกที่แสดง EGFR และ แกงกลิโอไซด์ N-ไกลโคลิล GM3 (NeuGcGM3)
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions